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The data from these focus groups should be viewed in light that the 
patients participating were all well enough to do so. Needs of people 
with more advanced disease (and their carers) may be different. 
Conclusions: This study contributes to increased understandings of the 
patient experience, and that of informal carers, to assist in the provision 
of information for decision making and in supporting patients in coping 
with NSCLC. These ﬁndings will also contribute to understandings 
of the experiences of NSCLC patients and carers, compared to those 
with other cancers. Care should be taken in ensuring that people with 
NSCLC do not “fall through the cracks” of treatment services and are 
able to ﬁnd the support they require. 
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Pharmacoeconomic analysis shows that erlotinib is cost-saving 
versus docetaxel, and cost-effective versus best supportive care 
(BSC) in NSCLC
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Background: Erlotinib is a potent, orally active inhibitor of EGFR 
tyrosine-kinase activity. In a randomised, phase III study (BR.21), erlo-
tinib was shown to signiﬁcantly prolong survival, delay symptom pro-
gression and improve quality of life compared with placebo in patients 
with relapsed NSCLC (Shepherd et al. NEJM 2005;353:123-32; Bezjak 
et al. JCO 2006;24:3831-7). The improvement in survival with erlotinib 
did not depend on tumour EGFR expression status. Using efﬁcacy data 
from the overall BR.21 population, combined with local health care 
utilisation data, we conducted a pharmacoeconomic analysis of erlo-
tinib in 2nd/3rd-line treatment of NSCLC in the Netherlands.
Methods: Two economic analyses were performed, one comparing er-
lotinib with docetaxel and the other with BSC. Efﬁcacy was expressed 
as life-years gained (LYG) and was calculated for erlotinib and BSC 
from the BR.21 intent-to-treat population. No head-to-head data are 
available for erlotinib and docetaxel, but clinical evidence suggests 
similar efﬁcacy (Ramalingam and Sandler, Oncologist 2006;11:655-
65). We therefore assumed LYG for docetaxel to be equal to that for 
erlotinib. LYG were extrapolated to 3 years following start of treatment 
to capture the survival data for all patients. Cost components were: 
frequency and duration of hospitalisation; outpatient consultations; 
radiotherapy; treatment of side effects; diagnostic procedures and labo-
ratory tests; drug use; and drug administration procedures. Dutch health 
care utilisation (HCU) data for patients with relapsed NSCLC were 
obtained by retrospective chart review (n=96). Twenty-four charts were 
analysed for patients treated with docetaxel, and 72 for those receiv-
ing BSC, from 4 general hospitals and 1 academic hospital. All prices 
were taken from 2004; except the erlotinib price (2005). Both cost and 
efﬁcacy results were discounted at 4%. Pharmacoeconomic analysis 
was performed with a Markov health-state model, using a base case and 
alternative scenarios. HCU data and model assumptions were approved 
by an expert panel of 10 Dutch lung cancer specialists.
Results: The average cost of treatment was €24,939 for docetaxel-
treated patients, compared with €23,436 for erlotinib-treated patients 
and €15,450 for patients on BSC. LYG were 0.84 years for docetaxel 
and erlotinib, and 0.62 years for BSC. Erlotinib was found to be cost 
saving versus docetaxel in most scenarios, except when assuming an 
unrealistically low dose of docetaxel (110mg/cycle). The incremental 
cost-effectiveness ratio (ICER) for erlotinib versus BSC was €37,551 
per LYG (CI €12,621-€72,960), based on an average treatment dura-
tion of 4.3 months. ICERs were sensitive to variations in the length and 
frequency of hospitalisation, as well as the number of outpatient con-
sultations. Assuming a willingness-to-pay (WTP) threshold of €50,000 
per LYG, and using the conﬁdence intervals of a select number of 
variables, erlotinib was found to be cost-effective compared with BSC 
in 80% of cases.
Conclusions: In patients with relapsed NSCLC, treatment with erlo-
tinib was found to be cost-saving versus docetaxel and cost-effective 
versus BSC. Based on the combined ﬁndings of clinical efﬁcacy and 
cost-effectiveness, erlotinib received unrestricted reimbursement in the 
Netherlands for patients with relapsed NSCLC.
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A phase 3 randomized, double blind, placebo-controlled study of 
patients with previously untreated extensive-stage small cell lung 
cancer (SCLC) treated with platinum plus etoposide chemotherapy 
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Background: Erythropoiesis-stimulating agents are widely used for the 
treatment of chemotherapy-induced anemia. Here we present results of 
a trial that evaluated the effect of darbepoetin alfa (DA) versus placebo 
on hemoglobin (Hb) concentration, survival, and disease progression in 
anemic cancer patients with previously untreated extensive-stage SCLC.
Methods: Patients with extensive-stage SCLC (n=597), ≥18-years old, 
and baseline Hb ≥9g/dL and ≤13g/dL, were randomly allocated 1:1 
DA:placebo. Randomization was stratiﬁed by region (Western Europe; 
Australia/North America; rest of world), performance status (0-1 versus 
2), and LDH (normal versus abnormal). DA 300µg or placebo was 
administered once per week (QW) for 4 weeks, then every 3 weeks 
(Q3W) until end of treatment. The dose was withheld if Hb increased 
≥14g/dL and resumed QW (weeks 1-4) or Q3W (week 5 to end of treat-
ment) once Hb dropped <13g/dL. Administration of study drug began 
with the ﬁrst cycle of on-study chemotherapy (cisplatin or carboplatin 
plus etoposide Q3W), continuing throughout 6 cycles. End-of-che-
motherapy period (EOCP) visits occurred up to 3 weeks after the last 
chemotherapy dose, and end-of-study treatment (EOST) visits occurred 
8 weeks after completion of chemotherapy; follow-up visits occurred 
every 3 months until death. Co-primary endpoints were mean change 
in Hb concentration during chemotherapy and survival. A prespeciﬁed 
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stepdown procedure allowed for statistical testing of survival (nomi-
nal P<0.025 for increased survival; <0.012 for decreased survival) if 
change in Hb was signiﬁcant at P<0.05. 
Results: Efﬁcacy and safety endpoints are presented in the table and 
graph.
Conclusions: DA administered 300µg QW followed by 300µg Q3W 
signiﬁcantly lessened reductions in Hb and signiﬁcantly reduced the in-
cidence of transfusions compared with placebo. There have been recent 
concerns relating to poorer survival in studies that targeted higher Hb 
levels; however, no difference in overall or progression-free survival 
was observed between the DA and placebo groups in this study.
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meaningful skeletal morbidity within a patient’s lifetime
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Background: Historically, approximately one third of patients with 
advanced lung cancer have developed bone metastases. Over time, 
malignant bone disease results in potentially disabling skeletal-related 
events (SREs) such as pathologic fracture, spinal cord compression, 
severe bone pain requiring radiotherapy, the requirement for orthopedic 
surgery, and hypercalcemia of malignancy. Within the past decade, 
therapeutic advances have produced signiﬁcant improvements in sur-
vival for patients with NSCLC. Therefore, we evaluated whether bone 
metastases have time to manifest in SREs within the lifetime of patients 
with NSCLC using a registration trial database from a large, random-
ized, controlled trial in patients with bone metastases from NSCLC or 
other solid tumors (Rosen LS, et al. Cancer. 2004;100:2613-2621).
Methods: A retrospective evaluation of SREs and survival was per-
formed on patients with NSCLC who were randomized to treatment 
with either zoledronic acid or placebo for up to 21 months (n = 378). 
All patients received concomitant antineoplastic therapy. Skeletal mor-
bidity was also analyzed using a robust survival-adjusted cumulative 
mean function.
Results: The trial in patients with bone metastases from solid tumors 
was conducted from August 1998 to January 2002, and the NSCLC 
patients had been diagnosed with bone metastases an average of 
approximately 4 months before enrollment. Median survival was 
approximately 6 months for these patients. However, within the ﬁrst 
6 months of this study approximately 50% of patients in the placebo 
group had experienced ≥ 1 SRE, more than 20% experienced ≥ 2 SREs, 
and more than 5% experienced ≥ 3 SREs. These analyses were adjusted 
for the effects of survival on skeletal morbidity. In the placebo group, 
the survival-adjusted cumulative mean incidence of events at 6 months 
was approximately 0.9 SREs per patient and approximately 0.5 events 
of radiation to bone per patient. 
Conclusions: These exploratory analyses of data from a multicenter in-
ternational trial show that patients with bone metastases from NSCLC 
experience skeletal morbidity within their lifetimes. Since this trial, 
additional treatment options have been developed that may prolong sur-
vival in this setting. As a result, increasing proportions of patients may 
develop SREs, which could decrease their quality of life and undermine 
their functional independence. Although these 6-month analyses were 
not statistically powered to detect treatment effects in the NSCLC stra-
tum, the results were consistent with the previously published analyses 
for the overall trial population in which zoledronic acid signiﬁcantly 
reduced the incidence of and delayed the onset of SREs during up to 21 
months of treatment.
